Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medical Research Council Technology and Biolex Therapeutics have announced that MRCT has successfully completed the humanization of a novel antibody targeting CD20, indicated in non-Hodgkin's lymphoma and rheumatoid arthritis.
Subscribe to our email newsletter
Biolex is applying its proprietary glycosylation optimization technology to the antibody, BLX-301, to enhance efficacy and potency of the product candidate and potentially reduce certain side effects.
Biolex will retain all development and commercialization rights to the humanized antibody, and Medical Research Council Technology (MRCT) will receive regulatory milestone payments and royalties upon its successful development.
Jan Turek, president & CEO of Biolex, said: “Applying the glycosylation optimization capabilities of our LEX System to a humanized antibody provides the potential for a next-generation product that offers a therapeutic advantage while also addressing the relatively low potency and problematic side-effect burden of the current standard of care.”